Institution Directory

Clinical trials at NIH Clinical Center

Sites in Bethesda, MD

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

777

Shown on this page

Current sort

Live official records

Conditions: Healthy Volunteer
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 5 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: fMRI
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 7 Years to 35 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain
Interventions: Not listed
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Motor Neuron Disease, Muscular Disease, Muscular Dystrophy, Peripheral Nervous System Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Very Rare Tumors, Very Rare Cancers, Other Solid Tumors, Solid Tumor, Pediatric Rare Tumors
Interventions: Natural history study of individuals with very rare tumors; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole, Methotrexate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
Interventions: Cyclophosphamide, Busulfan, Fludarabine, Total Body Irradiation, Hematopoietic stem cells, Tacrolimus, Mycophenolate Mofetil; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Neoplasms
Interventions: Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine, Sirolimus, Filgrastim, Cyclophosphamide, Mesna, Total Body Irradiation (TBI); Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Olaparib, Cediranib, Durvalumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms
Interventions: cyclophosphamide, fludarabine, TNhYP218 CAR T Cells, mesothelin expression testing; Drug · Biological · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Bethesda, Maryland

About this NIH Clinical Center institution page

What this page lists: ClinicalTrials.gov records that list NIH Clinical Center in Bethesda, MD as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NIH Clinical Center

Filter and sort this campus

Live official records

Normal Values in Hearing and Balance Testing

A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty

Screening Protocol

Study of Inherited Neurological Disorders

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

About this NIH Clinical Center institution page